Schrodinger upgraded by Morgan Stanley with a new price target
$SDGR
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley upgraded Schrodinger from Equal-Weight to Overweight and set a new price target of $82.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | $29.00 | Outperform | Leerink Partners |
| 12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
| 5/5/2023 | $60.00 | Overweight | Piper Sandler |
| 12/19/2022 | $23.00 | Neutral | Goldman |
| 3/1/2022 | $55.00 | Buy | Citigroup |
| 11/19/2021 | $82.00 → $49.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/19/2021 | $87.00 | Overweight | Piper Sandler |
| 11/11/2021 | $80.00 → $52.00 | Buy → Neutral | B of A Securities |
Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00
KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00
Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00
Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference. The live presentation will take place on Wednesday, December 4, 2024 at 8:30 a.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is lic
Schrödinger, Inc. (NASDAQ:SDGR) today reported that on November 14, 2024, the company granted restricted stock units (RSUs) with respect to 2,785 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs
– Additional funding received from the Bill & Melinda Gates Foundation to further accelerate initiative – Schrödinger, Inc. (NASDAQ:SDGR), today announced that it is broadening and accelerating its initiative to expand the company's computational platform to predict toxicology risk early in drug discovery. The goal of the initiative, announced earlier this year, is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects. In conjunction with this expansion, Schrödinger received an additional $9.5 m
Schrödinger to Receive $150 Million Upfront for New Multi-Target Collaboration with Novartis Third Quarter Total Revenue of $35.3 Million, Software Revenue of $31.9 Million Updates 2024 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier today, Schrödinger announced a multi-target research and licensing collaboration with Novartis. Under the terms of the agreement, Novartis will pay Schrödinger $150 million upfront, and Schrödinger will also be eligible to receive up to $2.3 billion in milestone payments. Schrödinger also announced an expanded three
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties Expanded multi-year software agreement enables technology deployment at significant scale across Novartis's global research organization Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis's portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödi
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
S-8 - Schrodinger, Inc. (0001490978) (Filer)
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $30.25, a high estimate of $37.00, and a low estimate of $25.00. This current average has decreased by 12.75% from t
Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $30 to $25.
Leerink Partners analyst Mani Foroohar initiates coverage on Schrodinger (NASDAQ:SDGR) with a Outperform rating and announces Price Target of $29.
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)